Clinical Trial Update: Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating orelabrutinib in combination with a R-CHOP-like regimen for newly diagnosed untreated non-GCB diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: UNKNOWN